The study by Boos SL underlined the capacity of KRAS wild-type CRC organoids to simulate and reproduce gradual chemotherapy tolerance to the combination of irinotecan and EGFR inhibition in vitro [168]. The gene discussed is EGFR; the disease is colorectal carcinoma.